{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-25-000006","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.970217+00:00","generated_at":"2026-05-28T04:57:35.958836+00:00","sec_items":["2.06"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AbbVie to record $3.5B impairment on emraclidine after Phase 2 schizophrenia failure","bullets":["Non-cash after-tax impairment charge of ~$3.5B on emraclidine intangible asset from Cerevel acquisition.","Two Phase 2 EMPOWER trials failed to meet primary endpoint: no significant reduction in PANSS total score vs placebo at week 6.","Remaining Cerevel-related intangible assets of ~$3.6B continue to be evaluated for potential impairment.","Impairment reflects significant decrease in estimated future cash flows for emraclidine."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-25-000006","json":"https://secwatch.observer/filing/0001551152-25-000006.json","markdown":"https://secwatch.observer/filing/0001551152-25-000006.md","text":"https://secwatch.observer/filing/0001551152-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000006/0001551152-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000006/abbv-20250109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:57:35.958836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52e245f7ca9526ba3974a5e130ce1de564da07b3","claim":"AbbVie Inc. announced a impairment with charges of approximately $3.5 billion affecting emraclidine intangible asset acquired as part of the acquisition of Cerevel Therapeutics Holdings, Inc..","evidence_excerpt":"the estimated future cash flows for the product. Based on the revised cash flows, the company estimates a non-cash after-tax intangible asset impairment charge of approximately $3.5 billion. AbbVie continues to evaluate information with respect to the Cerevel-related clinical development programs and will monitor the remaining intangible assets of approximately $3.6","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000006/0001551152-25-000006-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"approximately $3.5 billion"},{"label":"Affected area","value":"emraclidine intangible asset acquired as part of the acquisition of Cerevel Therapeutics Holdings, Inc."}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}